+1 (888) 794-0077
« Return
female scientist in lab

White Paper: Managing the Increasing Demands for Scientific Resources During the COVID-19 Pandemic

As our partners’ research and development programs begin to ramp up, so does the need for additional resources. At WuXi AppTec, we remain committed to ensuring the availability and integrity of the research models used on our customers’ vital development programs is maintained—all while ensuring steps are being taken in compliance with disease control guidelines pertaining to COVID-19.

Find out more about how WuXi AppTec is conducting scientific research in a COVID-19 world, providing quality testing support, keeping compounds in China and continuing to move programs forward with a healthy supply of research models.

Receive a copy of our white paper “Conducting Scientific Research in a COVID-19 World: Meeting the Demand for Animal Models”

Related Posts

Making the Most of the Golden Age of Small-Molecule Oncology Drugs

Making the Most of the Golden Age of Small-Molecule Oncology Drugs

Many of humanity’s most impactful pharmaceuticals, including penicillin and aspirin, are small-molecule drugs. Over time, the focus of research has shifted toward biologics, also known as large-molecule drugs. In 2016, for example, eight of the 10 best-selling drugs in the world were biologics. However, small-molecule drugs are now making a comeback as research advances and technology improves. One key area where small-molecule drugs are making the most significant impact is oncology. 

Evaluation of Immunogenicity for Oligonucleotide Drugs

Evaluation of Immunogenicity for Oligonucleotide Drugs

Drug research and development has evolved from focusing only on small molecule drugs into an era of advanced therapeutics. Among the pathogenic proteins related to human diseases, more than 80% belong to non-druggable targets. Meanwhile, most existing druggable targets are restricted by their structure and are difficult to develop.